Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study

Edouard J. Louis, Hervé E. Watier, Stefan Schreiber, Jochen Hampe, François Taillard, Allan Olson, Nicole Thorne, Hongyan Zhang, Jean-Frédéric Colombel
2006 Pharmacogenetics & Genomics  
Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of ≥ 70 points in the
more » ... 70 points in the Crohn's disease activity index or clinical remission (Crohn's disease activity index <150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes ( -79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P= 0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease.
doi:10.1097/01.fpc.0000230421.12844.fd pmid:17108815 fatcat:zrgil6sgpfbzlo52okfbnox4l4